Serial monitoring of clinical, haematological and immunological parameters in canine autoimmune haemolytic anaemia.
Clinical, haematological and immunological data are presented from 14 dogs with autoimmune haemolytic anaemia (AIHA) serially monitored for up to 945 days after initial presentation. At the time of diagnosis, all dogs had severe anaemia (mean packed cell volume [PCV] 17.6 +/- 7.1 per cent) with leucocytosis in seven cases and thrombocytopenia in four dogs. The Coombs' test was positive in all cases. Immunoglobulin G (IgG) autoantibody alone was identified in eight cases, a combination of IgG and IgM autoantibodies was recognised in three cases, and in two dogs only IgM autoantibody was recorded (complement fixing in one of these dogs). All dogs were treated with immunosuppressive doses of corticosteroids and some animals also received cyclophosphamide (four cases), azathioprine (two cases), blood transfusion (four cases) or underwent splenectomy (two cases). Two dogs died during the initial episode of AIHA. In 12 dogs, the anaemia was resolved by an average of 36.3 +/- 16.0 days after initial presentation, but autoantibody titre often persisted after clinical improvement and normalisation of PCV. Four dogs had a clinical relapse 67 to 170 days after initial presentation and one of these dogs subsequently died from thromboembolic disease. One dog developed lymphocytic thyroiditis and serum antinuclear antibody at day 691 after initial presentation, and two cases developed disease consistent with autoimmune thrombocytopenia (AITP) at 365 and 618 days post initial presentation. In one of these dogs, AITP was concurrent with multicentric lymphoma. No correlation was recorded between haematological and immunological parameters at presentation and subsequent response to therapy or long-term clinical behaviour.
Day
M J
MJ
Department of Pathology and Microbiology, University of Bristol, Langford.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000744:Anemia, Hemolytic, Autoimmune / Q000097:blood / Q000276:immunology / Q000662:veterinary*; D000818:Animals; D001379:Azathioprine / Q000627:therapeutic use; D001803:Blood Transfusion / Q000662:veterinary; D001810:Blood Volume; D003298:Coombs Test / Q000662:veterinary; D003520:Cyclophosphamide / Q000627:therapeutic use; D004283:Dog Diseases / Q000097:blood* / Q000276:immunology* / Q000628:therapy; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007958:Leukocyte Count; D008297:Male; D010976:Platelet Count; D013156:Splenectomy / Q000662:veterinary; D013921:Thrombocytopenia / Q000209:etiology / Q000401:mortality / Q000662:veterinary; D013967:Thyroiditis, Autoimmune / Q000209:etiology / Q000401:mortality / Q000662:veterinary
D000305:Adrenal Cortex Hormones; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D001379:Azathioprine